Cargando…
Beyond interferon
Interferon (IFN)-α has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group US
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096953/ https://www.ncbi.nlm.nih.gov/pubmed/18066029 http://dx.doi.org/10.1038/nbt1207-1375 |
| Sumario: | Interferon (IFN)-α has reigned supreme for decades as biotech's blockbuster antiviral. That looks set to change with a raft of antibody and nucleic acid therapies progressing through the pipeline. |
|---|